Lv21
138 积分 2024-11-19 加入
Optimization of a Second-Generation, Highly Selective Polθ/PARP1 Dual Inhibitor with Improved Pharmacokinetics and Potent Activity against HR-Deficient Tumors
56分钟前
待确认
Discovery of an orally bioavailable selenium-containing Polθ inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers
22天前
已完结
DNA damage induced by three major metabolites of 1,3-butadiene in human hepatocyte L02 cells
1个月前
已完结
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
2个月前
已完结
Rational Design and Biological Evaluation of a Novel Polθ Polymerase Inhibitor for Synergistic Targeting of HR-Deficient Cancers
2个月前
已完结
Identification and Targeting of POLQ -Associated Hereditary Colorectal Cancer
2个月前
已完结
Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers
2个月前
已完结
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ
5个月前
已关闭
TfR1-Binding Peptide Conjugation Facilitates Robust and Specific siRNA Delivery to the Central Nervous System
6个月前
已完结
EP.12H.08 SOHO-02: Phase III Trial of BAY 2927088 In Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations
11个月前
已关闭
皖公网安备34019202002308
